Overview

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Status:
Recruiting
Trial end date:
2023-02-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
2,4-thiazolidinedione
Biguanides
Dulaglutide
Glycoside Hydrolase Inhibitors